info@p-95.com

P95 welcomes John O’Brien as Chief Business Officer

We are excited to welcome John O’Brien as our new Chief Business Officer! John has a proven track record of driving commercial success and building strategic partnerships, bringing a wealth of experience to our team.I am delighted to welcome John to our team! His visionary leadership and innovative approach will be instrumental in driving our company forward as we continue our jounrey to be the premier provider of clinical and epidemiological services for vaccine developers worldwide.” – Thomas Verstraeten, P95 Chief Executive Officer John joins us from his previous role as Chief Commercial Officer at Excelya Group, a contract research organization (CRO) providing full-service clinical, FSP, and resourcing solutions. Prior to this, John held leadership and business development roles in various clinical CROs including Cmed, Chiltern, Theorem Clinical and Parexel. Please join us in extending a warm welcome to John! We are excited to have him on board and look forward to his valuable contributions to our organization’s continued success. Stay tuned for exciting updates as we embark on this new chapter together!
P95

Pioneering Clinical Excellence in Vaccines and Infectious Diseases

Tags:

You May Also Like

P95 Transforming Exercise into Charitable Impact

P95 Transforming Exercise into Charitable Impact

At P95, we believe in the power of movement – not just as a means to personal health, but as a catalyst for global change. Our Strava group, an initiative that promotes health and fitness within the team, has successfully translated the time logged over the last year into substantial donations for three charities that make a real difference.